Trials

University Hospitals Birmingham NHS Foundation Trust is a regional and national centre for specialist clinical services.

It is home to some of the country’s leading clinical research institutions, and is dedicated to developing and implementing groundbreaking treatments, technologies and techniques.

  • SORCE

    A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

    View Trial
  • A feasibility study of WorkPlan – a guided workbook intervention to support work-related goals among cancer survivors

    View Trial
  • MONOFER STUDY

    A randomized double-blinded comparative trial comparing the incidence of hypophosphatemia in relation to repeated treatment courses of iron isomaltoside and ferric carboxymalt-ose in subjects with iron deficiency anaemia due to inflamma-tory bowel disease

    View Trial
  • Epstein-Barr virus-induced T cell responses and the pathogenesis of Multiple Sclerosis

    View Trial
  • ENDCaP-C Test Accuracy Study

    Enhanced Neoplasia Detection and Cancer Prevention in Chronic Colitis (ENDCaPC) A Multicentre test accuracy study

    View Trial
  • JUNIPER

    AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144

    View Trial
  • IELSG 37

    A randomized open label multicentre two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-cell Lymphoma (PMLBCL)

    View Trial
  • EPIC III

    The Extended Study of Prevalence of Infection in Intensive Care III (EPIC III)

    View Trial
  • SABR CtE v2.0

    Commissioning Through Evaluation:Stereotactic Body Radiotherapy

    View Trial
  • A Phase 2 Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects with Moderately to Severely Active Ulcerative Colitis.

    View Trial